Biomarkers of drug-induced liver injury

Yong Zhou
Shizhen Qin
Kai Wang
Institute for Systems Biology, Seattle, WA, USA

Abstract: The liver plays a central role in metabolizing xenobiotics; therefore, it is highly susceptible to toxicity from these chemicals. Certain drugs, when taken in overdose and sometimes even when used within therapeutic range, may cause injury to the organ. Drug-induced liver injury is now not only a leading cause of acute liver failure in the US, but is also a leading reason for discontinuation of drugs in development and for regulatory actions against previously approved drugs. The current clinical biomarkers to detect and monitor drug-induced liver injury are inadequate in terms of sensitivity and/or specificity, prompting the need for more informative biomarkers. The development of high throughputs proteomics, genomics, and metabolomics technologies has the potential to fulfill such demand. The discipline of systems toxicology may add to our understanding of perturbed xenobiotic networks, which may lead to network-specific surrogate markers and therapeutic means to stop or reverse xenobiotic-induced liver injury.

Keywords: hepatotoxicity, idiosyncratic, metabolomics, genomics, proteomics, microRNA, systems toxicology

Introduction
Adverse effects associated with medicine used in clinics are a serious problem for patients and health care providers.1 It has been estimated that about 10% of drugs are associated with severe, undesirable side effects.2,3 However, the number is probably significantly underestimated given that drug-induced adverse effects are difficult to detect due to pre-existing medical conditions, multiple drug usage, and lack of diagnostic standards.1 Among all the major organs in the body, most drug-induced adverse effects are associated with the liver due to its active role in metabolizing xenobiotics. While the overall incidence of drug-induced liver injury (DILI) in the general population is largely unknown, the incidence of DILI attributed to an individual drug is estimated to be between one in 10,000 and one in 1,000,000 patient years for most medicines used in the clinic.4,5 Although the precise incident rate for DILI is difficult to establish, it has become the leading cause of drug development failure and post-approval usage restrictions or withdrawals.6,7 DILI is now the leading cause of acute liver failure, exceeding all other causes combined in Europe and North America.7,8 To address this challenging and often controversial issue, significant efforts have been focused on the identification of informative and predictive biomarker signatures for DILI through various globalomics-based molecular profiling approaches.9-11 In addition, multicenter research networks, such as the Drug-Induced Liver Injury Network, have begun to collect biological samples and develop approaches...
for the diagnosis, evaluation, and reporting of patients with suspected liver injury caused by the use of therapeutics and/or herbal products.9,12

Pathogenic mechanism of DILI

Even though the etiology of DILI is complicated and largely unknown, current knowledge can generally group the mechanisms into two major categories, ie, direct toxicity and indirect toxicity (Figure 1). Direct toxicity includes injuries caused directly by the xenobiotic or its metabolites, such as the toxic metabolite N-acetyl-p-benzoquinoneimine derived from acetaminophen.13 In conditions with high doses of acetaminophen exposure or low cellular glutathione concentration, N-acetyl-p-benzoquinoneimine binds to proteins and other macromolecules, interrupting their normal cellular activities, and leading to apoptosis of hepatocytes and centrilobular necrosis in the liver.14 Fortunately, most drug candidates and metabolites that induce significant direct toxicity can be screened out during the drug development process and seldom reach the market. However, obtaining a full safety profile for drugs is simply not possible due to cost and factors such as rare polymorphisms in drug-metabolizing enzymes and host immune response genes, as well as environmental factors. Certain drugs affecting a small number of patients can escape various safety screening steps in the drug development process and reach the market.2,15 For example, perhexiline [2-(2,2-dicyclohexylethyl)piperidine], an effective antianginal drug, when used in high doses, causes severe neurotoxicity and hepatotoxicity.16 However, at a standard dosage, certain individuals with mutations in cytochrome P450 2D6 (CYP2D6) isozyme, the key enzyme for metabolizing perhexiline, develop adverse effects due to their inability to process and excrete the drug at a normal rate.17 As a result, the drug was withdrawn from most countries in the late 1980s.

Indirect toxicity is a more complicated and less understood process. It usually involves an inflammatory process, including the activation of innate and/or adaptive immune responses.18 Sometimes additional events such as viral and/or bacterial infections and other drug usage are required to induce indirect toxicity.8 Minor hepatocellular dysfunction and cell death caused by therapeutic drugs or other factors may trigger the activation of cells involved in the innate immune system, such as Kupffer cells (resident macrophages of the liver) and natural killer cells.19 These cells may then exacerbate an initial minor injury by activating the adaptive immune system and producing proinflammatory mediators to recruit additional inflammatory cells to the liver.20 The key evidence that drugs activate the adaptive immune response is the ability to detect antibodies against drugs or their metabolites. For example, autoantibodies have been reported for halothane, dihydralazine, diclofenac, carbamazepine, tenilic acid, to name just a few.21 However, the link between activation of the adaptive immune system and DILI is still unclear. Despite the ability to segregate direct and indirect toxicity, the underlying mechanism for both types of DILI is not only complicated, but also difficult to study with existing technologies. Based on the incident pattern, there are two different types of DILI, predictable and idiosyncratic.22 Predictable toxicity usually shows a dose dependency with a short latency. Most predictable DILI is induced by drugs associated with direct toxicity.23 Acetaminophen is likely the most studied hepatotoxic drug, and gives a predictable toxicity in a dose-dependent fashion.14,19 Besides acetaminophen, there are a number of other drugs or supplements which are also known to cause predictable DILI. For example, amiodarone24 (an antiarrhythmic drug), isoniazid25 (the first-line drug in treating tuberculosis), and kava kava26 (an herbal supplement) are all known to show predictable dose-dependent hepatotoxicity. However, most instances of liver injury caused by drugs are unpredictable, and are termed idiosyncratic DILI.14,27,28 Unlike predictable adverse reactions, idiosyncratic reactions show no relationship with dose and occur with different latency, from one week to more than a year after the drug treatment.2 Idiosyncratic adverse reactions can be related
to interactions between the drug and host or environmental factors. In addition, how the host responds to the initial insults from drugs or their metabolites, including the ability to adapt, repair, and temper innate and adaptive immunity, might be as important as the factors involved in the initiation of liver injury.

**Types of pathology**

Even though all conceivable injuries induced by drugs have been seen in the liver, the injuries can generally be grouped into four major patterns, ie, the hepatitis, cholestatic, mixed, and other patterns based on the pathology (Figure 1). The hepatitis pattern is usually associated with hepatocellular injury. Patients with hepatitis display a wide spectrum of clinical manifestations from asymptomatic, fatigue, and pain to acute liver failure. Individuals usually show higher levels of serum aminotransferase activities. However, biochemical and clinical parameters often underestimate the degree of injury. Drugs such as acetaminophen, amiodarone, and isoniazid are known to cause hepatitis pattern DILI.

The cholestatic pattern is usually caused by cholangiocyte injury or inhibition of bilirubin or bile salt transport. Patients usually develop jaundice with elevation of blood alkaline phosphatase levels. This type of injury is usually less serious than the hepatitis pattern and typically does not develop into chronic liver disease. Drugs including amoxicillin, chlorpromazine, erythromycin, and estrogens are known to cause cholestatic DILI.

Certain drugs such as phenytoin, phenobarbital, and verapamil are known to cause a mixed type injury, a combination of hepatitis and cholestatic patterns. Patients usually have higher levels of both aminotransferases and alkaline phosphatase activities. This type of injury has a lower mortality rate compared with that of individuals with either hepatitis or cholestatic patterns. In addition to the three major patterns, certain drugs also induce other liver pathologies, including granulomas, fibrosis, neoplasms, steatohepatitis, and vascular lesions.

**Genetic markers used in detecting DILI**

Even though it does not account for all the risk factors, DILI is strongly affected by genetic predisposition, and especially by the polymorphisms associated with type I and II drug metabolizing enzymes. Various genetic polymorphisms in drug metabolizing enzymes and immunological mediators such as human leukocyte antigen (HLA) molecules and cytokines have been shown to correlate well with the patients’ susceptibility to DILI. A comprehensive list of the candidate genes can be found in recent reviews. The polymorphisms of these genes may be able to serve as markers to predict susceptibility of exposed individuals to DILI.

Advanced technologies such as genome-wide association studies (GWAS) and highly parallelized next-generation sequencing (NextGen) are now providing new methods to explore the association between genetic predisposition and DILI. For example, a GWAS study revealed that the HLA-B*5701 genotype is a major risk factor and ST6GAL1 is a possible cofactor of an individual’s vulnerability to fluclaxacillin-induced DILI. Whether the HLA-B*5701 genotype could serve as a new DILI biomarker for fluclaxacillin warrants further investigation. At present, the costs of GWAS or NextGen sequencing is still too high to be used in routine clinic screening. In addition, the predictive value for these genetic biomarkers to DILI is yet to be determined. Thus, at the present time, testing patients for the presence of susceptible genetic polymorphisms before prescribing a drug with potential DILI has very low clinical value. However, as more and more information is collected, it will be feasible to have a comprehensive pharmacogenetic test prior to prescribing certain drugs to determine an individual’s susceptibility to DILI, just like the association between CYP2C9 polymorphism and warfarin usage. The US Food and Drug Administration (FDA) has started a pilot process to explore the use of genomic biomarkers in FDA-approved drug labels. For example, N-acetyltransferase variants (associated with slow and fast acetylators of antituberculosis drugs) and the HLA-B*5701 allele (associated with the anti-human immunodeficiency virus drug abacavir), as potential genomic susceptibility markers for DILI.

**Blood biomarkers used in detecting DILI**

In addition to genetic markers, histological examination and imaging, the most common tests used in the clinic are based on the concentration changes of specific molecules in different body fluids, especially blood. Blood contains an array of biomolecules from small molecules to proteins. Many of the molecules in the circulation are the results of either cell lysis or metabolites to be excreted from the body. Therefore, the levels of specific biomolecules in the circulation may be used to assess the health status of the body. Different types of blood DILI biomarkers including metabolites, proteins, and RNAs have been reported in human and animal models, and examples are listed in Table 1.
Table 1 Examples of blood biomarkers for DILI and acute liver failure

<table>
<thead>
<tr>
<th>Name</th>
<th>Species</th>
<th>Body fluid</th>
<th>Drug compounds</th>
<th>Biomarker functions</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolite</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophthalmate</td>
<td>Rat</td>
<td>Serum</td>
<td>Acetaminophen</td>
<td>Hepatic glutathione depletion or oxidative stress</td>
<td>Soga et al(^64)</td>
</tr>
<tr>
<td>8-hydroxy-2′-deoxyguanosine</td>
<td>Human</td>
<td>Urine</td>
<td>Valproic acid</td>
<td></td>
<td>Lee et al(^25)</td>
</tr>
<tr>
<td>Octanoylcarnitine</td>
<td>Human</td>
<td>Urine</td>
<td>Valproic acid</td>
<td></td>
<td>Lee et al(^25)</td>
</tr>
<tr>
<td>Galactose</td>
<td>Rat</td>
<td>Blood</td>
<td>CCl(_3), INH and INH + BNPP</td>
<td>Liver functions</td>
<td>Young et al(^26)</td>
</tr>
<tr>
<td>Protein</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FL-K18 (M65)/cK18 (M30)</td>
<td>Human</td>
<td>Serum</td>
<td>Acetaminophen</td>
<td>Hepatocytic necrosis/apoptosis/outcome</td>
<td>Antoine et al(^63)</td>
</tr>
<tr>
<td>HMGB1 (total/acyetylated)</td>
<td>Human</td>
<td>Serum</td>
<td>Acetaminophen</td>
<td>Hepatocytic necrosis/immune cell activation</td>
<td>Rutherford et al(^64)</td>
</tr>
<tr>
<td>GDH</td>
<td>Human</td>
<td>Plasma</td>
<td>Acetaminophen</td>
<td>Mitochondrial dysfunction</td>
<td>Antoine et al(^63)</td>
</tr>
<tr>
<td>Caspase activation</td>
<td>Human</td>
<td>Plasma</td>
<td>Acute liver failure</td>
<td>Liver regeneration after ALF</td>
<td>McGill et al(^67)</td>
</tr>
<tr>
<td>DNA/RNA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA (mt/nuclear DNA fragments)</td>
<td>Human</td>
<td>Plasma</td>
<td>Acetaminophen</td>
<td>Mt dysfunction/nuclear DNA damage</td>
<td>McGill et al(^62)</td>
</tr>
<tr>
<td>RNA (Alb, Fga, and Hp)</td>
<td>Rat</td>
<td>Blood</td>
<td>Acetaminophen/D-gal</td>
<td></td>
<td>Miyamoto et al(^46)</td>
</tr>
<tr>
<td>MicroRNA miR-122, miR-192</td>
<td>Mouse</td>
<td>Plasma</td>
<td>Acetaminophen</td>
<td></td>
<td>Wang et al(^68)</td>
</tr>
<tr>
<td>MicroRNA miR-122</td>
<td>Mouse</td>
<td>Plasma</td>
<td>D-gal/alcohol</td>
<td></td>
<td>Zhang et al(^61)</td>
</tr>
<tr>
<td>MicroRNA miR-122</td>
<td>Mouse</td>
<td>Plasma</td>
<td>Chronic hepatitis B</td>
<td></td>
<td>Zhang et al(^61)</td>
</tr>
</tbody>
</table>

**Abbreviations:** Alb, albumin; ALF, acute liver failure; BNPP, bis-p-nitrophenyl phosphate; CCl\(_3\), carbon tetrachloride; cK18, caspase-cleaved fragment of keratin-18; DILI, drug-induced liver injury; Fga, fibrinogen alpha chain; FL-K18, full length keratin-18; D-gal, D-(+)-galactosamine; GDH, glutamate dehydrogenase; HMGB-1, high mobility group box-1; HP, haptoglobin; INH, isoniazid; mt, mitochondrial.

**Metabolite markers**

Metabolomics studies aim to reveal the profiles of small-molecule metabolites produced by cellular processes of an organ or the whole organism. In animal models, metabolomics investigations have identified a growing number of DILI biomarkers from different types of body fluids, such as serum and urine. For example, using a rat acetaminophen DILI model, serum ophthalmate was found to be a sensitive biomarker to reflect hepatic glutathione depletion or oxidative stress.\(^54\) The concentrations of 8-hydroxy-2′-deoxyguanosine and octanoylcarnitine in urine were also identified as indicators for valproic acid-induced DILI.\(^55\) The change in blood galactose levels has also been shown to be a better liver function indicator than the blood aminotransferase activities in animal models.\(^56\) The noninvasive nature of metabolomics markers in different types of body fluid samples makes them attractive; however, as with any biomarker identified, they require extensive validation with a large number of biological samples.\(^57\)

**Protein markers**

The most widely adopted DILI blood biomarkers are protein in nature, especially enzymes that are highly enriched in the liver, including aminotransferases, glutamate dehydrogenase, lactate dehydrogenase, and alkaline phosphatase. It is believed that when liver injury occurs, these abundant enzymes in hepatocytes leak into the blood stream.\(^58\) The changes in the activities or concentrations of these enzymes in blood should then reflect the degree of injury to the liver. The most commonly used aminotransferases for detecting DILI are glutamic pyruvate transaminase (GPT, also known as alanine aminotransferase) and glutamic-oxaloacetic transaminase, (GOT, also known as aspartate aminotransferase).\(^3\) Due to its molecular size, the half-life of GPT in serum is about 40–60 hours.\(^58\) An elevation of serum GPT activity is therefore an indication of damage that has occurred within the past 40–60 hours. Although it is generally believed that most of the enzyme activity tests have sufficient sensitivity, their specificity to DILI is often questionable. Extrahepatic expression of these liver-enriched enzymes is the main drawback for these markers. Therefore, injuries in other tissues may also cause changes in levels of these enzyme in blood.\(^59\) The lack of tests to distinguish different GOT and GPT isoenzyme activities further limit its usage. Despite these problems, elevation of serum aminotransferase levels/activities are still the most commonly used tests by pharmaceutical companies and regulatory agencies as indicators for DILI.\(^60\)
In addition to liver-enriched proteins and enzymes, many cytokines such as tumor necrosis factor alpha, interleukin (IL)1β and interleukin-6 have also been used as indicators for DILI, because inflammation is one of the key events in the initiation and progression of DILI. Recent epidemiological studies have also reported levels of several circulating proteins and their ratios as indicators/predictors for hepatocyte damage and repair. These proteins include full length cytokeratin-18 (K18), caspase-cleaved fragment of K18 (M30, indicating apoptosis and necrosis), high mobility group box-1 (HMGB1, indicating necrosis) and hyperacetylated HMGB1 (indicating apoptosis and immune cell activation). Combining the M30 level with clinical variables, including serum pH, body mass index, levels of creatinine, bilirubin, phosphorus, arterial ammonia, and lactate, gave a good association with the outcomes in patients with acute liver failure.

Zimmerman proposed the most widely adapted comprehensive test to detect DILI. The test includes the activities/concentrations of four different molecules in serum, GPT, GOT, alkaline phosphatase, and total serum bilirubin. These four biomarkers, along with an elevation of aminotransferases above three times the upper limit of normal and total serum bilirubin more than twice the upper limit of normal, have been known as Hy’s Law which is more effective in detecting serious liver injuries than elevation of aminotransferases alone.

RNA markers
Besides protein markers, several blood messenger RNA-based markers have also been shown to have good correlations with DILI. In rat DILI models, the levels of several “liver-specific” transcripts including albumin, fibrinogen, and haptoglobin genes in blood show significant elevations, along with blood aminotransferase activity after exposing rats to either acetaminophen or D- (+)-galactosamine. The concentrations of these mRNAs in blood were not affected if the animals were treated with bupivacaine, a chemical that causes muscle injury. However, in bupivacaine-treated rats, the levels of aminotransferase activity increased significantly in blood. This demonstrated the specificity of using mRNA-based biomarkers over traditional aminotransferase (protein)-based biomarkers to detect DILI.

Besides mRNA, a number of microRNAs in blood have also been reported as markers for DILI. MicroRNAs are small, single-stranded noncoding regulatory RNA molecules with an average length of about 20 nucleotides. They play a key role in modulating transcript and protein levels in cells. Since their discovery in the early 1990s, studies have shown that some of these important regulatory RNA molecules exist stably in various types of body fluid including blood and urine. The levels of some extracellular microRNAs show good correlations with various pathological conditions, such as cancers of various origins. The concentrations of two liver-enriched microRNAs in plasma, miR-122, and miR-192, were first found to have a good correlation with acetaminophen overdose induced-liver injury in animal models. The plasma levels of these two microRNAs show better sensitivity and specificity than blood GPT levels. The circulating miR-122 levels also reflected DILI induced by D- (+)-galactosamine. A more recent study showed that circulating miR-122 levels, but not serum GPT and GOT, could effectively differentiate liver injury from extrahepatic (ie, heart or muscle) injury. Based on the findings from these studies, the levels of specific circulating microRNAs in blood may perform better than the standard aminotransferase-based DILI biomarkers.

It is important to note that there is currently no perfect biomarker for DILI. Despite this deficiency, the combination of serum GPT, GOT, alkaline phosphatase, and total bilirubin levels continues to be the standard test for DILI, especially when measured consistently over the period of drug treatment. In the past decade, some progress has been made in developing better DILI biomarkers, such as attempts to develop isoenzyme-specific measurements of serum GPT levels and liver-enriched miRNA and mRNA levels in the circulation. Drug-specific biomarkers, such as blood acetaminophen-protein adducts, can also identify the etiology of DILI; however, this can only be applied for a limited number of drugs. It is worthwhile to point out that none of the above-mentioned new DILI biomarkers have been extensively validated.

Approaches for new biomarker discovery
While some DILI markers are effective in identifying potentially harmful drug candidates in the in vitro and in vivo models used in the drug development process, the current biomarkers lack the predictability, sensitivity, and specificity needed in the clinic. This is due to the diverse pathologies associated with drug-induced injuries and complex drug interactions in patients. More importantly, the current biomarkers are not able to pinpoint the type of injury, which is a vital necessity in clinic. Another major drawback is that the current DILI biomarkers are not suitable for detecting chronic liver injury. An example is chronic methotrexate-induced hepatotoxicity; there is no available
marker to detect and monitor the injury effectively, which forces some clinicians to use routine serial liver biopsies as an alternative to reduce the occurrence of severe DILI associated with methotrexate.76 Because DILI is a serious problem in health care, there is an urgent need to have biomarkers that can provide information for early detection, sufficient sensitivity of the injury, types of DILI, and prognosis of the injuries.77 Markers that can serve as predictors of response to treatment in patients with DILI are also in need.49 The advancement of various high throughput global molecular profiling technologies for proteins and nucleic acids has the potential to lead to more informative biomarkers.

High performance mass spectrometry (MS)-based protein identification and measurement has emerged as a key technology used to identify and validate protein biomarkers.78 For discovery, the process can be divided into two major approaches, ie, labeled and label-free methods. Development of the isobaric tags for relative and absolute quantitation method has simplified global protein quantitation.79 The main advantage of this approach is to reduce operation-related sample-to-sample variations, because all samples are mixed and processed at the same time after being labeled with different isobaric tags. The label-free approach is mainly based on the unique mass/charge (m/z) ratio of peptides to predict protein identity. This approach is computationally intense, and the accuracy of protein prediction depends on the completeness of the protein database.80 The drawback for MS-based biomarker discovery is the number of proteins (usually several hundred) that can be identified and quantified in each MS run. The recently developed selected reaction monitor (SRM) Atlas, combined with the “Swath” acquisition approach, significantly increases the number of proteins that can be detected and may have the capacity to systematically query any protein of interest in samples.81

Western blotting is the most commonly used method for validation. However, it can only be used on a limited number of samples and one protein marker at a time. It also depends on the availability of suitable antibodies.82 For a large number of samples, the MS-based selected reaction monitor approach is commonly used to quantify specific protein biomarkers accurately.83 This approach spikes in known concentrations of labeled heavy peptide(s) as a concentration standard, and uses mass spectrometer to detect and quantify the light (endogenous) and heavy (spiked in) peptides. The selected reaction monitor approach is also able to measure several proteins at the same time and is not limited to the availability of antibodies.84

Because most efforts at biomarker discovery aim to identify blood-based markers, the front-end sample processing plays an important role in the MS-based discovery approach.85 However, sample preparation can be a challenge due to the high complexity of blood samples. Protein concentrations in the circulation often span more than 10 orders of magnitude, and most of the proteins of interest in blood are at the lower end of the concentration spectrum.86 Enrichment processes, such as affinity column enrichment or depletion of highly abundant proteins, are a common practice for MS-based blood protein analysis.87 However, the need for significant front-end sample processing hinders the use of MS-based biomarker detection in the clinic. Once a protein biomarker is validated, the enzyme-linked immunosorbent assay is likely the most suitable method for routine clinical use, although developing proper reagents for an accurate and sensitive assay is nontrivial.

As with proteins, MS has evolved to be the most suitable platform to identify metabolomic markers.87 The small molecules in samples are usually fractionated via gas chromatography, high performance liquid chromatography, or capillary electrophoresis before injection into the MS for measurement.88 The human metabolome database (http://www.hmdb.ca) contains over 7000 small molecule metabolites derived from degradation of endogenous biomolecules, xenobiotics, and food components detected in the body.89 One of the biggest challenges in metabolomics is to pinpoint the origin of the metabolites.90 In the case of identifying biomarkers for xenobiotox-induced injuries, the xenobiotics themselves and their metabolites are useful markers to determine the drugs causing such effects. However, identifying the metabolites that reflect the type and severity of injury remains a challenge.87

Blood also contains a diverse range of RNA and DNA molecules. Several studies have already demonstrated the usefulness of using specific DNA or RNA sequences in the circulation, such as transcripts highly enriched in the liver, as markers to reflect DILI.11,67,91 The concentrations of these molecules are too low to conduct a global survey using traditional nucleic acid profiling approaches like microarray. Besides microRNA, due to its small repertoire, no systematic survey of the DNA or RNA spectrum in the circulation has been done. The recent development of next-generation sequencing requires much less starting material, which creates the possibility of conducting a comprehensive survey of the nucleic acid spectrum in blood to identify more informative nucleic acid-based biomarkers for xenobiotic-induced tissue injury.
It is important to point out that despite our ability to generate a list biomarker candidates using systematic global profiling, a number of useful biomarkers such as K-8 and its fragment, and mitochondrial and nuclear DNA fragments, have been identified through traditional approaches.62,63

Future prospects
Despite the technical advances in profiling biomolecules, identification of biomarkers from plasma or serum still poses many challenges. These include the diversity and wide concentration distribution of biomolecules in the circulation, complex post-transcriptional and post-translational modifications, the low concentration of molecules of interest, and the origin of the biomolecules in circulation. However, the biggest challenge is the integration of such global survey results. Systems toxicology, a discipline derived from systems biology, aims to integrate the results of different global molecular measurements to discover perturbed networks, build testable models, identify surrogate markers to reflect the perturbed network, and find methods to modulate or reverse the affected networks.92 The integration of multidimensional measurement results, including genomic, transcriptomic, proteomic, and metabolomic measurements, are a challenge due to our lack of understanding of how biomolecules interact in cells. In addition, a better understanding of higher-level interactions, such as how cells interact with each other in tissues and how tissues communicate in an organism, is clearly desirable. The basis of system toxicology is to generate and use animal models to evaluate the diversity of the human population, and to identify informative biomarkers and therapeutic strategies through the understanding of perturbed networks. Several studies using inbred mouse panels to explore the genetic contribution to the effects of xenobiotics are worth further investigation.

Acknowledgments
We thank Alton Etheridge for his critical comments. This work was supported by the University of Luxembourg program and research contracts from the Department of Defense (W911SR-07-C-0101, W81XWH-09-1-0107, and HDTA 1-08-C-0023).

Disclosure
The authors report no conflicts of interest in this work.

References


